Day: January 6, 2022

Enrollment of REDIRECT study (AFM13-202) is completed; topline clinical readout expected in 2H 2022 FDA approves protocol amendment to allow for (i) enrollment of up to 40 patients at the highest dose level, and (ii) treatment of patients with more than two cycles in the investigator sponsored trial of cord blood-derived natural killer (cbNK) cells pre-complexed with AFM13 (AFM13-104) Broad development strategy launched for AFM24 – enrollment initiated in three studies addressing major EGFR-expressing solid tumor indications including non-small cell lung and colorectal cancer For AFM28 a first in human study initiation is planned for second half of 2022 Cash position provides funding into 2H 2023HEIDELBERG, Germany, Jan. 06, 2022 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed...

ATLANTA, Jan. 06, 2022 (GLOBE NEWSWIRE) — Chart Industries, Inc. (NYSE: GTLS), a leading diversified global manufacturer of highly engineered equipment for the industrial gas and clean energy industries, will host an Investor Day at the New York Stock Exchange on Thursday, May 5, 2022. The Investor Day will begin at 7:30 a.m. ET and conclude by 11:30 a.m. ET. Members of Chart’s executive management team, including Jill Evanko, President and CEO, and Joe Brinkman, CFO, will provide an update on the company’s organic and inorganic strategic activities, ESG developments, commercial opportunities and operational execution including a three-year outlook across the company’s markets and segments. Registration for the Investor Day will open by March 4, 2022 and interested parties may register for the event on the Company’s investor...

WALTHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that Tillman Gerngross, Ph.D., chief executive officer of Adagio, is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 7:30 a.m. ET. A live webcast will be available in the investor section of the company’s website at investors.adagiotx.com and will be archived for 60 days following the presentations. About Adagio Therapeutics Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for...

TORONTO, Jan. 06, 2022 (GLOBE NEWSWIRE) — Consolidated Uranium Inc. (the “Company”, “CUR” or “Consolidated Uranium”) (TSXV: CUR) (OTCQB: CURUF) has been requested by OTC Markets Group Inc. (“OTC Markets”) to issue this statement about promotional activity concerning its common shares (the “Common Shares”). On January 3, 2022, OTC Markets informed the Company that it became aware of certain promotional activities concerning the Company and the Common Shares traded on the OTCQB Marketplace, including the distribution of three promotional newsletter e-mails published by The Wolf of Penny Stocks, Penny Picks and Epic Stocks Picks discussing the Company, its projects and the global uranium market. The publications also contained links to, and summaries of recent news releases issued by CUR. OTC Markets provided examples...

Research agreement combines Verily’s proprietary Immune Profiler platform with Sosei Heptares’ world-leading StaR® (stabilized receptor) platform and structure-based drug design capabilities TOKYO, Japan and CAMBRIDGE, United Kingdom and SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) — Sosei Group Corporation (“Sosei Heptares”; TSE: 4565) and Verily, an Alphabet precision health company, today announced they have entered into a strategic research collaboration. The research agreement brings together the complementary capabilities of Verily’s immune profiling and Sosei Heptares’ G-protein-coupled receptors (GPCR) structure-based drug design. The collaboration aims to:Advance the understanding of GPCR biology in immune cells, particularly in the fields of immunology, gastroenterology, immuno-oncology and other disorders...

At the Extraordinary General Meeting of Jyske Bank held today, the motions set out in the agenda were finally adopted. The motion concerning a reduction of Jyske Bank’s share capital and consequently amendment to Art. 2 of the Articles of Association as well as the authorisation of the general meeting to the Supervisory Board for registration of the Articles of Association were considered. The Danish Business Authority is subsequently requested to register the adopted motions. Yours faithfully, Jyske Bank Contact person: CFO, Birger Krøgh Nielsen, phone +45 89 89 64 44.AttachmentEGM_20220106

Partnership brings Seeing Machines’ industry leading OMS and DMS technology solutions to Ambarella’s CV2x CVflow® family of edge AI perception systems on chip (SoCs).Ambarella’s CV2x-based reference design platform performs the vision processing and fusion of Seeing Machines’ driver monitoring software with forward-facing Advanced Driver Assistance System (ADAS) features to provide a complete, integrated driver monitoring system (DMS) and ADAS solution.CANBERRA, Australia and SANTA CLARA, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) — Seeing Machines Limited (LSE: SEE), the advanced computer vision technology company that designs AI-powered operator monitoring systems to improve transport safety, announced a collaboration with Ambarella, Inc. (NASDAQ: AMBA), an AI vision silicon company, to bring integrated Advanced...